IN2013MU03610A - - Google Patents

Info

Publication number
IN2013MU03610A
IN2013MU03610A IN3610MU2013A IN2013MU03610A IN 2013MU03610 A IN2013MU03610 A IN 2013MU03610A IN 3610MU2013 A IN3610MU2013 A IN 3610MU2013A IN 2013MU03610 A IN2013MU03610 A IN 2013MU03610A
Authority
IN
India
Prior art keywords
dasatinib monohydrate
abstract
commercially
describes
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Guruprasad Ramchandra Wader
Dharmesh Mahendrabhai Shah
Original Assignee
Dharmesh Mahendrabhai Shah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dharmesh Mahendrabhai Shah filed Critical Dharmesh Mahendrabhai Shah
Priority to IN3610MU2013 priority Critical patent/IN2013MU03610A/en
Priority to PCT/IN2014/000782 priority patent/WO2015107545A1/en
Publication of IN2013MU03610A publication Critical patent/IN2013MU03610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
IN3610MU2013 2013-12-18 2014-12-17 IN2013MU03610A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3610MU2013 IN2013MU03610A (ja) 2013-12-18 2014-12-17
PCT/IN2014/000782 WO2015107545A1 (en) 2013-12-18 2014-12-17 Water soluble salts of dasatinib hydrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3610MU2013 IN2013MU03610A (ja) 2013-12-18 2014-12-17

Publications (1)

Publication Number Publication Date
IN2013MU03610A true IN2013MU03610A (ja) 2015-04-24

Family

ID=53039939

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3610MU2013 IN2013MU03610A (ja) 2013-12-18 2014-12-17

Country Status (2)

Country Link
IN (1) IN2013MU03610A (ja)
WO (1) WO2015107545A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2006121742A2 (en) 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor
EP1909795B1 (en) 2005-06-09 2011-04-13 Bristol-Myers Squibb Company Pharmaceutical composition for use in treating individuals exhibiting mutant kit protein
WO2007035874A1 (en) 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
WO2010139979A2 (en) * 2009-06-03 2010-12-09 Generics [Uk] Limited Processes for preparing crystalline forms
NZ630288A (en) * 2012-04-20 2015-08-28 Shilpa Medicare Ltd Process for preparing dasatinib monohydrate

Also Published As

Publication number Publication date
WO2015107545A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12016500169A1 (en) Polymorph of syk inhibitors
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IN2013MU00646A (ja)
IN2014MU00455A (ja)
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
IN2013MU03862A (ja)
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
IN2014CH00304A (ja)
HUE040536T2 (hu) Eljárás halogén-N,N-dimetilbenzilaminok elõállítására
IN2013MU01111A (ja)
IN2013MU01113A (ja)
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IN2013MU04056A (ja)
PT2981518T (pt) Um processo melhorado para a preparação de maleato de fluvoxamina
HUP1400104A2 (en) Compositions comprising indometacine, its pharmaceutically acceptable salts and cocrystals; and process for the preparation
IN2013MU03610A (ja)
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2013CH04314A (ja)
IN2013MU03565A (ja)
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2014CH01391A (ja)
IN2013CH04330A (ja)
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.